Chiesi Farmaceutici S.p.A

EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

European Commission (EC) · rare disease · 5 min

The European Commission has expanded Lojuxta's indication to include children aged 5 years and older with homozygous familial hypercholesterolemia. This analysis covers the regulatory shift, implications for Chiesi's rare disease franchise, and what investors and BD teams should monitor next.